Pulse.

a daily field guide to health research that matters

◆ Console

‹ Mon · 2 Nov 2026
Near-term implementable finding

Prognostic Impact of FLT3-ITD Microclones in AML: An EHA AML-Specialized Working Group Study

Identifying tiny FLT3-ITD mutations could help doctors better predict which AML patients need more aggressive treatment despite current risk classifications.

This EHA AML Working Group multicenter study evaluated FLT3-ITD microclones (allelic ratio <0.05) and found they independently predict inferior outcomes despite 2022 ELN intermediate-risk reclassification. Results directly challenge current AML risk stratification and have immediate implications for treatment selection, consolidation strategy, and transplant allocation.

What the study was

Study design
Retrospective multicenter cohort study
Population
AML patients with FLT3-ITD mutation across multiple European centers
Category
Genomics/Precision Medicine
Maturity
Validated
Journal
American journal of hematology

Why it surfaced

Multicenter EHA Working Group study challenging ELN 2022 AML risk stratification; FLT3-ITD microclone detection has direct clinical utility for treatment planning in high-mortality disease.

A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.